These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15828237)

  • 21. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
    Garmes HM; Tambascia MA; Zantut-Wittmann DE
    Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin resistance in polycystic ovarian disease.
    Bhatia V
    South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between vitamin D
    Kaminska K; Grzesiak M
    J Physiol Pharmacol; 2021 Feb; 72(1):. PubMed ID: 34099581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Insulin sensitizers in the treatment of polycystic ovary].
    Ortiz Núñez DA; Hernández Marín I; Ayala AR
    Ginecol Obstet Mex; 2005 Jun; 73(6):315-27. PubMed ID: 16309038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
    Sharma ST; Nestler JE
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic therapy of polycystic ovary syndrome.
    Dronavalli S; Ehrmann DA
    Clin Obstet Gynecol; 2007 Mar; 50(1):244-54. PubMed ID: 17304039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.
    Du Q; Yang S; Wang YJ; Wu B; Zhao YY; Fan B
    Adv Ther; 2012 Sep; 29(9):763-74. PubMed ID: 22932791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin-sensitizing agents in women with polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Fertil Steril; 2006 Jul; 86 Suppl 1():S28-9. PubMed ID: 16798283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment.
    Garruti G; Depalo R; Vita MG; Lorusso F; Giampetruzzi F; Damato AB; Giorgino F
    Reprod Biomed Online; 2009 Oct; 19(4):552-63. PubMed ID: 19909598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
    Liao L; Tian YJ; Zhao JJ; Xin Y; Xing HY; Dong JJ
    Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
    Glintborg D; Støving RK; Hagen C; Hermann AP; Frystyk J; Veldhuis JD; Flyvbjerg A; Andersen M
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5605-12. PubMed ID: 16076946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical inquiries. Do insulin-sensitizing drugs increase ovulation rates for women with PCOS?
    Andy C; Flake D; French L
    J Fam Pract; 2005 Feb; 54(2):156, 159-60. PubMed ID: 15689292
    [No Abstract]   [Full Text] [Related]  

  • 35. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    Tan S; Hahn S; Benson S; Dietz T; Lahner H; Moeller LC; Schmidt M; Elsenbruch S; Kimmig R; Mann K; Janssen OE
    Eur J Endocrinol; 2007 Nov; 157(5):669-76. PubMed ID: 17984248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
    Hurliman A; Keller Brown J; Maille N; Mandala M; Casson P; Osol G
    Endocrinology; 2015 Nov; 156(11):4071-80. PubMed ID: 26322372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
    Li XJ; Yu YX; Liu CQ; Zhang W; Zhang HJ; Yan B; Wang LY; Yang SY; Zhang SH
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):332-9. PubMed ID: 21050251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome.
    Qi X; Yun C; Liao B; Qiao J; Pang Y
    J Endocrinol; 2020 May; 245(2):281-289. PubMed ID: 32163914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.